Annual Accounts Receivable
$11.80 M
+$10.33 M+701.02%
31 December 2023
Summary:
C4 Therapeutics annual accounts receivable is currently $11.80 million, with the most recent change of +$10.33 million (+701.02%) on 31 December 2023. During the last 3 years, it has risen by +$7.32 million (+163.14%). CCCC annual accounts receivable is now -86.35% below its all-time high of $86.44 million, reached on 31 December 2018.CCCC Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$10.34 M
+$9.17 M+786.12%
30 September 2024
Summary:
C4 Therapeutics quarterly accounts receivable is currently $10.34 million, with the most recent change of +$9.17 million (+786.12%) on 30 September 2024. Over the past year, it has increased by +$9.84 million (+1968.20%). CCCC quarterly accounts receivable is now -23.96% below its all-time high of $13.60 million, reached on 31 March 2024.CCCC Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CCCC Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +701.0% | +1968.2% |
| 3 y3 years | +163.1% | +113.4% |
| 5 y5 years | -86.3% | - |
CCCC Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +701.0% | -24.0% | +1968.2% |
| 5 y | 5 years | -86.3% | +701.0% | -24.0% | +1968.2% |
| alltime | all time | -86.3% | +701.0% | -24.0% | +1968.2% |
C4 Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $10.34 M(+786.1%) |
| June 2024 | - | $1.17 M(-91.4%) |
| Mar 2024 | - | $13.60 M(+15.3%) |
| Dec 2023 | $11.80 M(+701.0%) | $11.80 M(+2259.8%) |
| Sept 2023 | - | $500.00 K(-51.4%) |
| June 2023 | - | $1.03 M(+94.7%) |
| Mar 2023 | - | $528.00 K(-64.2%) |
| Dec 2022 | $1.47 M | $1.47 M(-1.0%) |
| Sept 2022 | - | $1.49 M(-12.9%) |
| June 2022 | - | $1.71 M(-3.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $1.77 M(-69.0%) |
| Dec 2021 | $5.72 M(+27.5%) | $5.72 M(+18.0%) |
| Sept 2021 | - | $4.84 M(-22.0%) |
| June 2021 | - | $6.21 M(+69.9%) |
| Mar 2021 | - | $3.66 M(-18.5%) |
| Dec 2020 | $4.48 M(-3.0%) | $4.48 M(+8.3%) |
| Sept 2020 | - | $4.14 M(-51.5%) |
| June 2020 | - | $8.55 M(+84.9%) |
| Dec 2019 | $4.62 M(-94.7%) | $4.62 M |
| Dec 2018 | $86.44 M | - |
FAQ
- What is C4 Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for C4 Therapeutics?
- What is C4 Therapeutics annual accounts receivable year-on-year change?
- What is C4 Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for C4 Therapeutics?
- What is C4 Therapeutics quarterly accounts receivable year-on-year change?
What is C4 Therapeutics annual accounts receivable?
The current annual accounts receivable of CCCC is $11.80 M
What is the all time high annual accounts receivable for C4 Therapeutics?
C4 Therapeutics all-time high annual accounts receivable is $86.44 M
What is C4 Therapeutics annual accounts receivable year-on-year change?
Over the past year, CCCC annual accounts receivable has changed by +$10.33 M (+701.02%)
What is C4 Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of CCCC is $10.34 M
What is the all time high quarterly accounts receivable for C4 Therapeutics?
C4 Therapeutics all-time high quarterly accounts receivable is $13.60 M
What is C4 Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, CCCC quarterly accounts receivable has changed by +$9.84 M (+1968.20%)